MDXG insider trading
NasdaqCM HealthcareMIMEDX GROUP, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About MIMEDX GROUP, INC.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
Company website: www.mimedx.com
MDXG insider activity at a glance
FilingIQ has scored 362 insider transactions for MDXG since Jun 18, 25. The most recent filing in our index is dated Mar 13, 2026.
Across the full history, 11 open-market purchases
and 77 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MDXG insider trades is 57.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MDXG Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding MDXG
Frequently asked
- How many insider trades does FilingIQ track for MDXG?
- FilingIQ tracks 362 Form 4 insider transactions for MDXG (MIMEDX GROUP, INC.), covering filings from Jun 18, 25 onwards. 18 of those were filed in the last 90 days.
- Are MDXG insiders net buyers or net sellers?
- Across the full Form 4 history for MDXG, 11 transactions (3%) were open-market purchases and 77 (21%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MDXG insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MDXG in?
- MIMEDX GROUP, INC. (MDXG) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $773.09M.
Methodology & sources
Every MDXG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.